Tango Pharma - TNGX Net earnings per share for the last four quarters

Official company branding of Tango Pharma (TNGX)

Tango Therapeutics focuses on precision cancer therapy through synthetic lethality by developing targeted molecules. The company is currently scaling its innovative portfolio and validating drug candidates. The business is shielded from macroeconomic shocks and is not subject to seasonality. The annual net income per share growth rate (ttm) clearly illustrates the capital dynamics, where the -50.40 mark serves as a real-time assessment of current efficiency.

Tango Therapeutics, Inc. (TNGX) Earnings per share for the last twelve months: for the period 02/11/2024 - 11/17/2026

TNGX (Tango Therapeutics, Inc.): analytical breakdowns and indicator data

Initial company analysis:TNGX, Tango Pharma
Mass-produced product of tangotx.com

Assessing the financial stability of Tango Therapeutics (TNGX) requires an analysis of the business's ability to convert research and development into actual revenue. The current YoY ttm net income per share growth, standing at -50.40, measures the annual change in profit over 12 months, which is critical for a biotech company at the commercialization stage of targeted oncology drugs for genetic deletions.

Direct competitors

Earnings per share for the trailing year IBRX (ImmunityBio)|IMCR: Net earnings per share (EPS TTM)|JANX - Net earnings per share for the last four quarters|Earnings per share for the last twelve months arcusbio.com|Net earnings per share for the last 12 months zymeworks.com (ZYME)|Earnings per share for the last twelve months Iovance Biotherapeutics Inc (IOVA)|Net earnings per share for the last 12 months Immatics Corp IMTX|Xencor Inc - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Compass Therapeutics Corp CMPX|REPL - Earnings per share for the last twelve months|LYEL (lyell.com) - Earnings per share for the last 12 months|Innate Pharma S.A (IPHA) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Pyxis Oncology, Inc. (PYXS)|Net earnings per share for the last 12 months CGEN|IOBT - Net earnings per share for the trailing year|Net earnings per share for the last 12 months STRO (Sutro Bio)|Earnings per share for the last four quarters INKT|Net earnings per share (EPS TTM) HOWL (Werewolf Therapeutics)|Earnings per share for the trailing year IMMX|alxoncology.com - Net earnings per share (EPS TTM)|Earnings per share for the trailing year CUE (Cue Biopharma)|PDS Biotechnology Corp (PDSB) - Earnings per share for the last twelve months|Sonnet BioTherapeutics Holdings, Inc. - Earnings per share for the trailing year|MAIA (MAIABiotech.com) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Liminatus Pharma Inc.|Earnings per share for the last twelve months lavatherapeutics.com (LVTX)|NXTC: Earnings per one share for the last 12 months|Leap Therapeutics - Net earnings per share for the last 12 months|Intensity Tx (INTS) - Net earnings per one share for the last twelve months|SNSE - Earnings per share for the last twelve months|Theriva Biologics - Earnings per share for the last four quarters|Gritstone Bio (GRTS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Kineta, Inc. (KA)|Net earnings per share for the last 12 months NEXI|TSBX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) VCNX|HARP: Earnings per one share for the last 12 months